SCHEMBL9360

SCHEMBL9360

C=CCNO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9362 1.00
Water SCHEMBL5487305 0.96
Hydrochloric Acid SCHEMBL277848 0.96
SCHEMBL4149569 0.96
SCHEMBL1965919 0.96
Hydrochloric Acid SCHEMBL3433151 0.93 TSHR (0.38)
Hydrochloric Acid SCHEMBL7039746 0.93
Hydroxyamine SCHEMBL17187300 0.93
SCHEMBL10629515 0.90
SCHEMBL15466682 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933082-B2 Materials and methods for suppressing and/or treating neurofibroma and related tumors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) 2015-01-13 US claimed
US-8765777-B2 Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection EMORY UNIVERSITY (US) 2014-07-01 US claimed
US-20140121214-A1 MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) 2014-05-01 US claimed
US-20120071491-A1 Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2012-03-22 US claimed
US-20110281867-A1 COMPOSITIONS AND METHODS OF USE FOR TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-11-17 US claimed
US-20110201619-A1 Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders HEINRICH MICHAEL 2011-08-18 US claimed
US-20110195975-A1 MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING NEUROFIBROMA AND RELATED TUMORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-08-11 US claimed
EP-1725295-B1 COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION UNIV EMORY (US) 2010-09-15 EP claimed
US-20100210596-A1 USE OF AMINOPYRIMIDINE COMPOUNDS IN THE TREATMENT OF IMMUNE DISORDERS NIH-DIETR 2010-08-19 US claimed
US-20090221519-A1 COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND NOVARTIS AG (CH) 2009-09-03 US claimed
WO-2002022597-A1 N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES NOVARTIS AG (CH) 2002-03-21 WO claimed
WO-2001064200-A2 USE OF PDGF RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DIABETIC NEPHROPATHY NOVARTIS AG (CH) 2001-09-07 WO claimed
WO-2001047507-A2 COMBINATIONS OF RECEPTOR TYROSINE KINASE INHIBITOR WITH AN A1-ACIDIC GLYCOPROTEIN BINDING COMPOUND NOVARTIS AG (CH) 2001-07-05 WO claimed
EP-0564409-B1 Pyrimidin derivatives and process for their preparation NOVARTIS AG (CH) 2000-01-19 EP claimed
US-5612340-A ANTITUMOR AGENTS CIBA-GEIGY CORPORATION (US) 1997-03-18 US claimed
US-5521184-A ANTITUMOR AGENTS; imatinib mesylate CIBA-GEIGY CORPORATION (US) 1996-05-28 US claimed
EP-0672035-A1 PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1995-09-20 EP claimed
WO-1995009847-A1 PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF CIBA-GEIGY AG (CH) 1995-04-13 WO claimed
US-5244879-A 23-nor-23-oxa avermectin analogs are active anthelmintic agents MERCK & CO., INC. (US) 1993-09-14 US claimed
US-5162363-A 23-nor-23-thia avermectin analogs are active anthelmintic agents MERCK & CO., INC. (US) 1992-11-10 US claimed